No Detail Found!

Analysis of Cytokeratin-18 Levels in COVID-19 Patients

Author(s)
Nur Chumairoh Department of Clinical Pathology, Faculty of Medicine,Universitas Airlangga, Surabaya,Indonesia
Puspa Wardhani Aryati Clinical Pathology Residency Program, Department of Clinical Pathology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia; Department of Clinical Pathology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia; Department of Clinical Pathology, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia
Yessy Puspitasari Department of Clinical Pathology, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia
Abstract
COVID-19, in its early stages, causes severe acute respiratory distress syndrome (ARDS) and acute respiratory symptoms. The administration of Remdesivir in severe COVID-19-infected patients may result in liver damage, also known as Drug-Induced Liver Injury (DILI). Cytokeratin-18 (CK-18) is a potential biomarker for liver inflammation and injury in COVID19-infected individuals, particularly those receiving antiviral therapies such as Remdesivir. Objective: This study evaluates CK-18 levels as an indicator of DILI and its correlation with the inflammatory marker interleukin-6 (IL6) in COVID-19-infected individuals. Methods: A retrospective case-control study was carried out on 176 samples, separated into three distinct groups: 63 critical or severe COVID-19-infected patients treated in the intensive care unit (ICU-admitted group), 88 moderate COVID-19-infected patients treated in general hospital wards (non-ICU-admitted group), and 25 healthy individuals serving as the control group. CK-18, IL-6, and liver enzyme levels were measured, and statistical analysis was performed to identify substantial differences and correlations. Results: The CK-18 levels of the patients admitted to the ICU were substantially higher than those who were not and the control group (p < 0.001). Post-Remdesivir therapy, CK-18 levels increased significantly (p < 0.001). A substantial positive connection was found between CK-18 and IL-6 levels (p = 0.001), highlighting their combined role in inflammation and liver injury. Conclusion: CK-18 and IL-6 can serve as predictive biomarkers for liver damage and inflammation in COVID-19 patients, particularly those requiring critical care. These findings underscore the need for further research into CK-18's application in managing severe COVID-19 cases.
Publication Details
Page(s) 4594-4599
Published Journal: Pakistan Journal of Life and Social Sciences, Volume: 23, Issue: 1, Year: 2025

Request the full text from PASTIC

Keywords
Cytokeratin-18 (CK-18) COVID-19 Remdesivir Therapy Interleukin-6 (IL-6)
References
Bertolini A,IP van de Peppel F,Bodewes H,Moshage A,Fantin F,Farinati F,Pathogenesis Potential .2020 .Abnormal Liver Function Tests in Patients With COVID-19: Relevance. , 72 : 1864-1872.
Costela-Ruiz VJ,Illescas-Montes R,Puerta-Puerta JM,Ruiz C,Melguizo-Rodríguez L .2020 .SARSCoV-2 infection: The role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev, 54 : 62-75.
Gao YM,Xu G .2021 .Cytokine storm syndrome in coronavirus disease 2019: A narrative review. Journal of Internal Medicine, 289 : 147-161.
Henry BM,Cheruiyot I,Benoit SW,Sanchis-Gomar F,Lippi and J Benoit G .2022 .Cytokeratin 18 cell death assays as biomarkers for quantification of apoptosis and necrosis in COVID-19: a prospective, observational study. Journal of Clinical Pathology, 75 : 410-415.
Jothimani D,Kaliamoorthy I,Rela M .2020 .-19 and the liver. Journal of Hepatology, 73 : 1231-1240.
Korver S,Bowen J,K Pearson J,French N,Park K .2021 .The application of cytokeratin-18 as a biomarker for drug-induced liver injury. Archives of Toxicology, 95 : 3435-3448.
Licata A,MG Minissale M,Distefano G,Montalto G .2021 .Liver injury, SARS-COV-2 infection and COVID-19: What physicians should really know? GastroHep,. , 3 : 121-130.
Mangalmurti N .2020 .. Understanding COVID-19. Immunity, 53 : 19-25.
Marjot T,Z Stamataki T,Wong VW .2021 .-19 and liver disease: mechanistic and clinical perspectives. Nature Reviews: Gastroenterology & Hepatology, 18 : 348-364.
Nogai L,K Singh and R Bohra L .2021 .Dealing with SARS COV-2 pandemic: perusing remdesivir and hydroxychloroquine as therapeutic alternative. European Journal of Molecular & Clinical Medicine, 7 : 2132-2148.
Pawlotsky J-M .2020 .-19 and the liver-related deaths to come. Nature Reviews Gastroenterology & hepatology, 17 : 523-525.
Sun X,T Wang D,Cai Z,Hu J,Chen H,Liao H .2020 .Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev, 53 : 38-42.
Vitiello A,Porta R La,'Aiuto V D,Ferrara F .2021 .The risks of liver injury in COVID-19 patients and pharmacological management to reduce or prevent the damage induced. Egypt Liver J, 11 : 11.
Ye Q,Wang and J Mao B .2020 .The pathogenesis and treatment of the `Cytokine Storm' in COVID-19. Journal of Infection, 80 : 607-613.
0

Citations

0

Downloads

63

Views